Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Treating Patients With Essential Thrombocytopenia

January 30th 2020

Treatment of Myelofibrosis: Emerging Therapies

January 30th 2020

Combining Ruxolitinib With Other Agents

January 30th 2020

The Role of Fedratinib in Myelofibrosis

January 30th 2020

The Use of Ruxolitinib in Myelofibrosis

January 30th 2020

Symptom Control in Myelofibrosis

January 30th 2020

Risk Stratification in Myelofibrosis

January 30th 2020

Symptoms, Diagnosis, and QoL in Patients With Myelofibrosis

January 30th 2020

Can Hepcidin Reduce Iron Deficiency in Phlebotomy?

January 30th 2020

Role of Phlebotomy in Polycythemia Vera

January 30th 2020

Goals of Therapy in Polycythemia Vera

January 30th 2020

Signs of Progressive Polycythemia Vera

January 30th 2020

Common Signs and Symptoms of Polycythemia Vera

January 30th 2020

An Overview of Myeloproliferative Neoplasms

January 30th 2020

Dr. Kremyanskaya on Effect of CPI-0610 in Patients With Myelofibrosis

January 29th 2020

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Dr. Mesa on JAK Inhibitors in the Pipeline for Myelofibrosis

January 28th 2020

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Dr. Gerds on Addressing Anemia in Myelofibrosis

January 28th 2020

Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.

Dr. Dunavin on Ongoing Research for Myelofibrosis Treatments

January 28th 2020

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

Genomic Sequencing and Identifying Driver Mutations in AML and MDS

January 25th 2020

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

January 24th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.